Publicat pe

DEXCOM LAUNCHES INNOVATIVE NEW SENSOR, DEXCOM ONE+, BRINGING SMARTER, EASIER, AND MORE EFFECTIVE DIABETES MANAGEMENT TO ROMANIA

  • Dexcom ONE+ is available today in Romania, meaning people with Type 1 and Type 2 diabetes now have an easier way to manage their condition and see their glucose readings, without painful fingerpricks*.
  • New system continues to ensure more people can gain access to accurate1, easy-to-use†2, real-time continuous glucose monitoring (CGM1).
  • Dexcom ONE+ uses Dexcom’s best-in-class, most accurate, sensor design and incorporates user and prescribing doctor feedback.

BUCHAREST – April 26, 2024 – DexCom, Inc., a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, together with Deyan Kraft Medical, today announced the launch of their latest CGM system, Dexcom ONE+. Dexcom ONE+ uses Dexcom’s best-in-class and most accurate sensor design. Dexcom also incorporated feedback from both end users and healthcare professionals when building Dexcom ONE+, ensuring an easy-to-use, highly effective, CGM experience for people treating their Type 1 or Type 2 diabetes with insulin.

„Diabetes is a chronic condition that effects so many aspects of my life. Managing my glucose levels is absolutely crucial for me and for anyone living with diabetes. Dexcom ONE+ meets our needs, gives me a really clear picture of where my glucose levels are and what direction they are going, and it makes our lives closer to normal!”Dragoș Bucur, actor and diabetes patient.

For people still managing diabetes using fingerpricks and regularly injecting insulin, their lives can feel overwhelmed by diabetes. Dexcom ONE+ was developed to take away some of this burden, it’s designed to be easy to get started with** and easier to live with, even for those with no experience of using a CGM system. Like all Dexcom CGM, Dexcom ONE+ gives a clear picture of what glucose levels are doing in real-time, without painful fingerpricks*, therefore making it easier for people to achieve lasting results§, 3, ‡‡5 ,6. Importantly, for loved ones, Dexcom ONE+ also allows a user to easily share their glucose numbers with up to ten people, offering everyone a little more peace of mind†† 7-8.

Compared to fingerpricks, a CGM sensor provides a much clearer picture of how daily choices affect glucose levels and this data has the potential to lead to life-long behavioural changes for diabetes management.” says Alexandra Crișan, Diabetologist.

Dexcom sensors are known for their ease of use, accuracy, and reliability and with the launch of Dexcom ONE+ in Romania I hope more people will gain access to these powerful diabetes management tools.

We are really proud to announce the launch of Dexcom ONE+ and to offer this product to the diabetes community in Romania.” Said Radu Putere, CEO of Deyan Kraft Medical, official distributor of Dexcom in Romania.

People in Romania with insulin-treated diabetes can now gain access to Dexcom’s best and most accurate technology, either through the platform www.cgmmdiabet.ro or through the Romanian National Diabetes Program (for patients with Type 1 diabetes and gestational diabetes).”

Features that set Dexcom ONE+ apart from other CGM systems include multiple possibilities for personalisation and flexibility. Dexcom ONE+ offer the most discretion, with three wear location options‡ 1,4 and  is the only CGM available in Romania that offers 30 minutes warm-up period, 12 hours grace period and the ‘delay first high’1  alert. Furthermore, designed to fit seamlessly into a user’s life, Dexcom ONE+ also has the highest waterproof rating when compared to other CGM brands, allowing users to confidently continue using their device while showering or exercising.

To find out more information about how Dexcom ONE+ can benefit you or your loved one speak to your doctor, request a Dexcom ONE+ user manual, or visit  www.cgmdiabet.ro

About Deyan Kraft Medical

Deyan Kraft Medical is a leader in innovative technologies and systems for diabetes management therapy in Romania. At every moment, the Deyan Kraft Medical team is mobilized around a single goal: improving the quality of life for the diabetes community by combining state-of-the-art technology, innovative products designed to help users manage their diabetes more easily, to and improve their quality of life and have access to the treatments they need. For more information about Deyan Kraft Medical, visit www.cgmdiabet.ro

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

† Results obtained with Dexcom G7, which shares the same wearable as Dexcom ONE+
* If the glucose alerts and readings do not match symptoms a blood glucose meter should be used to make diabetes treatment decisions.
** Compared to previous generation Dexcom CGM System, Dexcom ONE
‖ Compared to Blood Glucose Meter patient use
*Results obtained with a previous generation of Dexcom CGM system and are applicable to Dexcom ONE+ given similar feature sets and better performance and usability.
‡‡ Study included non-Dexcom CGM system
‡ Dexcom ONE+ is approved for wear on the arm and abdomen, and children 2-6 years can also wear their sensor on the upper buttocks
¶The Dexcom ONE+ Sensor is waterproof and may be submerged under 2.4 Meters of water for up to 24 hours without failure when properly installed.
†† Separate Follow app and internet connection required
1 Dexcom ONE+ User Guide, 2023. 2. Dexcom Data on file 2022.  3 Lind M, et al. Diabetes Care. 2021;44(1):141-149. 4. Freestyle Libre 2, Medtronic and Senseonics User Guides. 5 Soupal J, et al. Diabetes Care. 2020; 43: 37-43. 6 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 7 Polonsky WH et al. Diabetes Technol Ther. 2021;23(3):195-202. 8 Polonsky WH et al. J Diabetes Sci Technol. 2022;16(1):97-105
Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *

Acest site folosește Akismet pentru a reduce spamul. Află cum sunt procesate datele comentariilor tale.